BRL-26921

Known as: BRL 26921, BRL26921 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1981-2004
02419812004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The thrombolytic properties of anisoylated plasminogen streptokinase activator complex (BRL 26921) and clinical results of the… (More)
Is this relevant?
1987
1987
We report the results of two consecutive studies using intravenous bolus injections of streptokinase (SK) or acylated plasminogen… (More)
Is this relevant?
1986
1986
Fifty patients with a first myocardial infarction presenting within 4 hours of the onset of symptoms were treated with… (More)
Is this relevant?
1986
1986
The safety and fibrinolytic efficacy of a new anisoylated plasminogen-streptokinase activator complex (APSAC) was tested in 50… (More)
Is this relevant?
1986
1986
BRL 26921 is a new acylated streptokinase-plasminogen complex which may have a more specific local thrombolytic effect than… (More)
Is this relevant?
1985
1985
BRL 26921 is a protected plasminogen-streptokinase complex with selective affinity for thrombus. When given intravenously within… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1985
1985
The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems… (More)
Is this relevant?
1985
1985
The role of thrombus-binding in the fibrinolytic response to the acylated streptokinase.plasminogen activator complex, BRL 26921… (More)
Is this relevant?
1984
1984
The fibrinolytic efficacy and systemic effects on coagulation variables of intracoronary administration of an acylated… (More)
Is this relevant?
1984
1984
In view of current interest in the possibility of rapid, high-dose administration of thrombolytic agents by the intravenous route… (More)
Is this relevant?